- Home
- AUTL vs XOMA Comparison
AUTL vs XOMA Comparison
Compare AUTL & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- XOMA
- Stock Information
- Founded
- AUTL 2014
- XOMA 1981
- Country
- AUTL United Kingdom
- XOMA United States
- Employees
- AUTL N/A
- XOMA N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- XOMA Health Care
- Exchange
- AUTL Nasdaq
- XOMA Nasdaq
- Market Cap
- AUTL 415.2M
- XOMA 457.6M
- IPO Year
- AUTL 2018
- XOMA N/A
- Fundamental
- Price
- AUTL $1.76
- XOMA $36.35
- Analyst Decision
- AUTL Strong Buy
- XOMA Strong Buy
- Analyst Count
- AUTL 5
- XOMA 2
- Target Price
- AUTL $9.12
- XOMA $69.50
- AVG Volume (30 Days)
- AUTL 4.8M
- XOMA 54.2K
- Earning Date
- AUTL 11-11-2025
- XOMA 11-06-2025
- Dividend Yield
- AUTL N/A
- XOMA N/A
- EPS Growth
- AUTL N/A
- XOMA N/A
- EPS
- AUTL N/A
- XOMA N/A
- Revenue
- AUTL $29,934,000.00
- XOMA $44,952,000.00
- Revenue This Year
- AUTL $641.63
- XOMA $88.91
- Revenue Next Year
- AUTL $109.21
- XOMA $13.80
- P/E Ratio
- AUTL N/A
- XOMA N/A
- Revenue Growth
- AUTL 185.17
- XOMA 194.98
- 52 Week Low
- AUTL $1.11
- XOMA $18.35
- 52 Week High
- AUTL $5.00
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- AUTL 48.20
- XOMA 55.52
- Support Level
- AUTL $1.45
- XOMA $36.41
- Resistance Level
- AUTL $1.65
- XOMA $39.92
- Average True Range (ATR)
- AUTL 0.10
- XOMA 1.96
- MACD
- AUTL 0.03
- XOMA -0.31
- Stochastic Oscillator
- AUTL 56.09
- XOMA 58.26
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.